Kedalion Therapeutics Inc., of Menlo Park, Calif., said it completed a $5 million series A financing led by Lagunita Biosciences. Proceeds will be used to further develop the company's Acustream technology platform through to pilot-scale GMP manufacturing and support advancement of clinical programs.